PROTEIN POLYMER TECHNOLOGIES NAMES JAMES B. MCCARTHY
TO BOARD OF DIRECTORS
SAN DIEGO,
April 25 -- Protein Polymer Technologies, Inc. (OTC BB: PPTI), announced
today that James B. McCarthy, M.B.A., J.D. has been elected to its Board of
Directors. Having recently selected a new CEO, PPTI is expanding the Board of
Directors.
“
James McCarthy brings over 30 years of global experience in the healthcare,
medical device, and biotech manufacturing fields to our company,” said
William N. Plamondon, PPTI’s newly appointed CEO. “His expertise
in planning and analysis will prove to be a great asset to our Board.”
McCarthy is Chairman and Chief Executive Officer of Gemini Consulting Group,
Inc., Oak Brook, IL., a company specializing in the development of hospitals
and specialty medical facilities in both the U.S. and overseas. He has also
held senior management positions for a Chicago-based health care consulting
company, a medical device manufacturing company, and the Medical Products Division
of 3M Company. McCarthy has a BA from the University of Notre Dame, a J.D. from
Loyola University School of Law, and an MBA from the Keller Graduate School
of Management. He sits on several boards including Wintrust Financial Corporation,
Lake Forest, IL. (NASDAQ, WTFC), and Sirigen, Inc., Santa Barbara, CA. “I
am delighted to be joining the Board of Protein Polymer Technologies”,
said McCarthy. “I look forward to working with the Board and Management
on the expansion and ongoing development of the company’s exciting technologies
and products.”
Contacts:
J. Thomas Parmeter, Ph.D.
Chairman
Protein Polymer Technologies, Inc.
(858) 558-6064
info@ppti.com
|
Erin Davis
Director of Communications and Investor Relations
Protein Polymer Technologies, Inc.
(858) 558-6064 x 120
edavis@ppti.com
|
About
Protein Polymer Technologies
Protein Polymer Technologies, Inc., is a San Diego-based company focused
on developing products to improve medical and surgical outcomes. From its inception
in 1988, PPTI has been a pioneer in protein design and synthesis, creating
an extensive portfolio of proprietary biomaterials for use in the development
of bioactive devices. These genetically engineered biomaterials are high molecular
weight proteins, processed into products with physical and biological characteristics
tailored to specific clinical performance requirements. Targeted products include
urethral bulking agents for the treatment of stress urinary incontinence, dermal
augmentation products for cosmetic and reconstructive surgery, surgical adhesives
and sealants, scaffolds for wound healing and tissue engineering, and depots
for local drug delivery. To date, PPTI has been issued twenty-six U.S. Patents
on its core technology with corresponding issued and pending patents in key
international markets.
Safe Harbor
This press release contains forward-looking statements
that are based on management’s views and expectations.
Actual results could differ materially from those expressed
here; further, the Company is not obligated to comment
specifically on those differences. Risks associated with
the Company’s activities include raising adequate
capital to continue operations scientific and product
development uncertainties, competitive products and approaches,
continuing collaborative partnership interest and funding,
regulatory testing and approvals, and manufacturing scale
up. The reader is encouraged to refer to the Company’s
2004
Annual Report Form 10-KSB, and other recent filings
with the Securities and Exchange Commission, copies of
which are available from the Company, to further ascertain
the risks associated with the above statements.
